Results 31 to 40 of about 2,139 (156)

Case Report: Infantile Bullous Pemphigoid: Triggering by COVID-19 Is Speculative

open access: yesFrontiers in Medicine, 2021
Bullous pemphigoid (BP) is a cutaneous disease triggered by numerous stimuli, where genetic milieu-influenced autoimmunity to hemidesmosomal proteins, namely, BP180 and/or BP230 initiate an inflammation leading to dermal-epidermal junction (DEJ ...
Anna Rosińska-Więckowicz   +3 more
doaj   +1 more source

Serological Insights into Bullous Pemphigoid: Comparative Diagnostic Performance and Their Association with Clinical Severity

open access: yesClinical Dermatology Review
Background: Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease caused by autoantibodies targeting BP180 and BP230. We evaluated the diagnostic performance of anti-BP180-NC16A and anti-BP230 enzyme-linked immunosorbent assay (ELISA ...
Mohan Shendre   +5 more
doaj   +1 more source

Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05:05 and -DRB1*07:01, in Germans

open access: yesOrphanet Journal of Rare Diseases, 2021
Bullous pemphigoid (BP) is the most common autoimmune skin blistering disease characterized by autoimmunity against the hemidesmosomal proteins BP180, type XVII collagen, and BP230. To elucidate the genetic basis of susceptibility to BP, we performed the
Christian Schwarm   +34 more
doaj   +1 more source

Paraneoplastic Pemphigus Presenting as Mild Cutaneous Features of Pemphigus Foliaceus and Lichenoid Stomatitis with Antidesmoglein 1 Antibodies

open access: yesDermatology Research and Practice, 2010
Herein, we report a case of paraneoplastic pemphigus with mild skin features of pemphigus foliaceus and lichenoid stomatitis associated with B-cell lymphoma. A 49-year-old man presented with scattered blisters and erosions on the trunk along with mucosal
Yayoi Niimi   +5 more
doaj   +1 more source

Emerging Paediatric Uses of Dupilumab Beyond Approvals

open access: yesClinical &Experimental Allergy, EarlyView.
Dupilumab, through IL‐4Rα blockade, shows promising efficacy beyond approved indications in paediatric diseases driven by T2 inflammation. Emerging evidence—mainly from small studies—supports improvements in disease severity and quality of life, highlighting its potential as a targeted, steroid‐sparing therapy while underscoring the need for ...
Simone Foti Randazzese   +11 more
wiley   +1 more source

Structural basis of integrin α6β4 interaction with the bullous pemphigoid antigen BP230 in hemidesmosomes

open access: yes, 2018
Mechanical stability of epithelia requires firm attachment of the cells to the basement membrane via complexes named hemidesmosomes. Disorders that target hemidesmosomal proteins cause severe skin blistering diseases. In type I hemidesmosomes, present in
Alonso-Garcia   +7 more
core   +1 more source

Effect and length of doxycycline administration in elderly patients with bullous pemphigoid

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background Bullous pemphigoid (BP) is the most common autoimmune blistering disease and primarily affects the elderly. Systemic corticosteroids and immunosuppressive drugs are the standard treatment, but side effects often restrict their use. Doxycycline has been proposed as an alternative, but there is limited long‐term, real‐world data on its
Alena Merkel‐Ropele   +2 more
wiley   +1 more source

Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications

open access: yesImmunology, EarlyView.
PSTPIP2 acts as a key brake on myeloid inflammation by suppressing IL‐1β‐driven signalling, macrophage dysregulation and inflammation‐associated bone remodelling. Its emerging roles in CRMO/CMO, rheumatoid arthritis, SAPHO syndrome and bullous pemphigoid support its potential as a biomarker and therapeutic target.
Erdong Zhang   +9 more
wiley   +1 more source

A Case of Bullous Rash Apparently Triggered by Meningococcal and Rotavirus Vaccines in an Infant: Focus on Infantile Bullous Pemphigoid

open access: yesDermatopathology, 2021
Bullous pemphigoid (BP) is an autoimmune bullous disease and is a rare condition in childhood. Acquired tense acral bullae and fixed urticarial annular lesions on the trunk are diagnostic clues of infantile BP.
Iria Neri   +4 more
doaj   +1 more source

Incidence of P200 pemphigoid: A nationwide study

open access: yesJournal of the European Academy of Dermatology and Venereology, Volume 40, Issue 10, Page 1675-1681, October 2026.
The anti‐LAMB4 cell‐based immunoassay is a new serological technique that is far superior to dermal immunoblotting for detecting autoantibodies directed against the P200 protein. This method allows a re‐evaluation of the incidence of P200 pemphigoid, which appears to be considerably more frequent than epidermolysis bullosa acquisita.
Fabienne Jouen   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy